Thomas A. Luger
University of Münster
EndocrinologySurgeryPathologyMolecular biologyDermatologyProinflammatory cytokineReceptorChemistryImmunologyPimecrolimusInflammationAtopic dermatitisCytokineMelanocortinPsoriasisClinical trialMedicineBiologyImmune systemCell biology
500Publications
95H-index
22.4kCitations
Publications 491
Newest
#1Thomas A. Luger (WWU: University of Münster)H-Index: 95
Last. Zuotao Zhao (PKU: Peking University)
view all 15 authors...
Atopic dermatitis is a chronic relapsing, inflammatory skin disorder associated with skin barrier dysfunction, the prevalence of which has increased dramatically in developing countries. In this article, we propose a treatment algorithm for patients with mild-to-moderate and severe atopic dermatitis flares in daily clinical practice. An international panel of 15 dermatology and allergy experts from eight countries was formed to develop a practical algorithm for the treatment of patients with ato...
Source
#1Thomas A. Luger (WWU: University of Münster)H-Index: 95
#2Masayuki Amagai (Keio: Keio University)H-Index: 91
Last. Matthias Schmuth (Innsbruck Medical University)H-Index: 52
view all 13 authors...
Abstract Atopic dermatitis (AD) is a chronic, inflammatory skin disorder characterized by eczematous and pruritic skin lesions. In recent decades, the prevalence of AD has increased worldwide, most notably in developing countries. The enormous progress in our understanding of the complex composition and functions of the epidermal barrier allows for a deeper appreciation of the active role that the skin barrier plays in the initiation and maintenance of skin inflammation. The epidermis forms a ph...
Source
#1Thomas A. Luger (WWU: University of Münster)H-Index: 95
#2Matthias AugustinH-Index: 61
Last. Thomas Werfel (MHH: Hannover Medical School)H-Index: 86
view all 9 authors...
Atopic dermatitis (AD) is a common skin disease during infancy, which imposes a considerable burden on patients, their families, and the society, requiring effective treatment options that result in rapid and sustained symptom relief. Additionally, early treatment may prevent the development of atopic comorbidities by restoring the skin barrier. Currently, topical standard-of-care for AD in infants includes emollients and topical corticosteroids (TCS) to treat and reduce the risk of flares. Howe...
2 CitationsSource
#1Jacob P. Thyssen (UCPH: University of Copenhagen)H-Index: 70
#2Chuanbo Zang (Pfizer)H-Index: 6
Last. Thomas A. Luger (WWU: University of Münster)H-Index: 95
view all 8 authors...
INTRODUCTION Atopic dermatitis (AD) severity was measured in two phase 3 US studies of crisaborole ointment, 2%, in patients aged ≥ 2 years using the Investigator's Static Global Assessment (ISGA), an FDA-recommended scale. Eczema Area and Severity Index (EASI) is a validated scale used globally to assess AD severity in clinical trials. The objective of this study is to aid interpretability of ISGA by translating ISGA scores to EASI scores. METHODS ISGA was mapped to EASI using published EASI se...
Source
#1Eric L. Simpson (OHSU: Oregon Health & Science University)H-Index: 62
#2Wynnis L. Tom (Boston Children's Hospital)H-Index: 20
Last. Daniela E. Myers (Pfizer)H-Index: 4
view all 10 authors...
The Investigator’s Static Global Assessment (ISGA) is a 5-point rating scale that is recommended by the US Food and Drug Administration for assessing the severity of atopic dermatitis (AD), and ISGA success is a widely used endpoint in AD clinical studies. In this study, we seek to interpret the relationship of ISGA with treatment, pruritus, and quality of life (QoL) by conducting post hoc analyses of pooled data from two phase 3 crisaborole studies. Patients aged ≥ 2 years with baseline ISGA of...
Source
#1Thomas A. Luger (WWU: University of Münster)H-Index: 95
Source
#1David C K Luk (United Christian Hospital)H-Index: 7
#2Kam Lun Hon (CUHK: The Chinese University of Hong Kong)H-Index: 33
Last. Thomas A. Luger (WWU: University of Münster)H-Index: 95
view all 10 authors...
Introduction There is some evidence to suggest that the prevalence of atopic dermatitis (AD) in Asia is rising. We have therefore developed an algorithm for the topical treatment of AD throughout South and East Asia for use by primary care physicians, pediatricians and dermatologists. Methods Nine AD experts from South and East Asia and one from Europe developed the algorithm based upon treatment guidelines, relevant literature and local treatment practices. The algorithm outlines current best p...
Source
#1Giampiero Girolomoni (University of Verona)H-Index: 80
#2Thomas A. Luger (WWU: University of Münster)H-Index: 95
Last. Marco DiBonaventura (Pfizer)H-Index: 29
view all 7 authors...
Atopic dermatitis (AD) is a common inflammatory disease of the skin, which may have a substantial impact on patients' health-related quality of life (HRQoL). The aim of this study was to quantify the economic burden (direct and indirect costs) of moderate-to-severe AD and evaluate the prevalence and impact of psychosocial comorbidities among patients in the European Union-5 (France, Germany, Italy, Spain, and the UK). Data were analyzed from the 2017 EU5 National Health and Wellness Survey. Resp...
2 CitationsSource
#1L. GossecH-Index: 3
Last. Kati OtsaH-Index: 10
view all 27 authors...
Source
Source